Genotypes of catechol-O-methyltransferase and response to levodopa treatment in patients with Parkinson's disease

Myung Sik Lee; Chul Hyoung Lyoo; Ismo Ulmanen; Ann Christine Syvänen; Juha O Rinne

doi:10.1016/S0304-3940(00)01749-3

Genotypes of catechol-O-methyltransferase and response to levodopa treatment in patients with Parkinson's disease

Myung Sik Lee, Chul Hyoung Lyoo, Ismo Ulmanen, Ann Christine Syvänen, Juha O Rinne

Department of Neurology

Research output: Contribution to journal › Article › peer-review

50 Citations (Scopus)

Abstract

A single nucleotide polymorphism at the nucleotide 1947 in the catechol-O-methyltransferase (COMT) gene encodes the high and low activity forms of the enzyme. We investigated COMT genotypes of 73 Korean patients with Parkinson's disease (PD), 29 with multiple system atrophy (MSA), and 49 controls, and analyzed the response to levodopa challenge in the PD patients. We found no significant difference in the distribution of the COMT genotypes among the three groups. The frequencies of the G- and A-alleles in the total population were 75 and 25%, respectively. The levodopa response was determined by a single oral levodopa challenge test with Sinemet^® (25/250 mg) in the patients with PD. The motor response evaluated by the time to peak response, the duration and magnitude of the response in the motor part of the Unified Parkinson's Disease Rating Scale; tapping or walking times showed no significant difference between the genotypes. Thus, pharmacokinetic or pharmacodynamic factors other than the investigated genetic variant of the COMT enzyme seem to determine the response to levodopa in PD.

Original language	English
Pages (from-to)	131-134
Number of pages	4
Journal	Neuroscience Letters
Volume	298
Issue number	2
DOIs	https://doi.org/10.1016/S0304-3940(00)01749-3
Publication status	Published - 2001 Feb 2

Bibliographical note

Funding Information:
We thank Päivi Tainola and Mari Sipilä (National Public Health Institute, Helsinki) for technical assistance with the genotyping assays. This study was supported by the CMB-YUHAN research grant of the Yonsei University College of Medicine for 1998. JOR was supported by the Päivikki and Sakari Sohlberg Foundation and the EVO funds of the Turku University Hospital.

All Science Journal Classification (ASJC) codes

Neuroscience(all)

Access to Document

10.1016/S0304-3940(00)01749-3

Cite this

@article{238890cecbd24446a0691925cc5a9224,

title = "Genotypes of catechol-O-methyltransferase and response to levodopa treatment in patients with Parkinson's disease",

abstract = "A single nucleotide polymorphism at the nucleotide 1947 in the catechol-O-methyltransferase (COMT) gene encodes the high and low activity forms of the enzyme. We investigated COMT genotypes of 73 Korean patients with Parkinson's disease (PD), 29 with multiple system atrophy (MSA), and 49 controls, and analyzed the response to levodopa challenge in the PD patients. We found no significant difference in the distribution of the COMT genotypes among the three groups. The frequencies of the G- and A-alleles in the total population were 75 and 25%, respectively. The levodopa response was determined by a single oral levodopa challenge test with Sinemet{\textregistered} (25/250 mg) in the patients with PD. The motor response evaluated by the time to peak response, the duration and magnitude of the response in the motor part of the Unified Parkinson's Disease Rating Scale; tapping or walking times showed no significant difference between the genotypes. Thus, pharmacokinetic or pharmacodynamic factors other than the investigated genetic variant of the COMT enzyme seem to determine the response to levodopa in PD.",

author = "Lee, {Myung Sik} and Lyoo, {Chul Hyoung} and Ismo Ulmanen and Syv{\"a}nen, {Ann Christine} and {O Rinne}, Juha",

note = "Funding Information: We thank P{\"a}ivi Tainola and Mari Sipil{\"a} (National Public Health Institute, Helsinki) for technical assistance with the genotyping assays. This study was supported by the CMB-YUHAN research grant of the Yonsei University College of Medicine for 1998. JOR was supported by the P{\"a}ivikki and Sakari Sohlberg Foundation and the EVO funds of the Turku University Hospital.",

year = "2001",

month = feb,

day = "2",

doi = "10.1016/S0304-3940(00)01749-3",

language = "English",

volume = "298",

pages = "131--134",

journal = "Neuroscience Letters",

issn = "0304-3940",

publisher = "Elsevier Ireland Ltd",

number = "2",

}

TY - JOUR

T1 - Genotypes of catechol-O-methyltransferase and response to levodopa treatment in patients with Parkinson's disease

AU - Lee, Myung Sik

AU - Lyoo, Chul Hyoung

AU - Ulmanen, Ismo

AU - Syvänen, Ann Christine

AU - O Rinne, Juha

N1 - Funding Information: We thank Päivi Tainola and Mari Sipilä (National Public Health Institute, Helsinki) for technical assistance with the genotyping assays. This study was supported by the CMB-YUHAN research grant of the Yonsei University College of Medicine for 1998. JOR was supported by the Päivikki and Sakari Sohlberg Foundation and the EVO funds of the Turku University Hospital.

PY - 2001/2/2

Y1 - 2001/2/2

N2 - A single nucleotide polymorphism at the nucleotide 1947 in the catechol-O-methyltransferase (COMT) gene encodes the high and low activity forms of the enzyme. We investigated COMT genotypes of 73 Korean patients with Parkinson's disease (PD), 29 with multiple system atrophy (MSA), and 49 controls, and analyzed the response to levodopa challenge in the PD patients. We found no significant difference in the distribution of the COMT genotypes among the three groups. The frequencies of the G- and A-alleles in the total population were 75 and 25%, respectively. The levodopa response was determined by a single oral levodopa challenge test with Sinemet® (25/250 mg) in the patients with PD. The motor response evaluated by the time to peak response, the duration and magnitude of the response in the motor part of the Unified Parkinson's Disease Rating Scale; tapping or walking times showed no significant difference between the genotypes. Thus, pharmacokinetic or pharmacodynamic factors other than the investigated genetic variant of the COMT enzyme seem to determine the response to levodopa in PD.

AB - A single nucleotide polymorphism at the nucleotide 1947 in the catechol-O-methyltransferase (COMT) gene encodes the high and low activity forms of the enzyme. We investigated COMT genotypes of 73 Korean patients with Parkinson's disease (PD), 29 with multiple system atrophy (MSA), and 49 controls, and analyzed the response to levodopa challenge in the PD patients. We found no significant difference in the distribution of the COMT genotypes among the three groups. The frequencies of the G- and A-alleles in the total population were 75 and 25%, respectively. The levodopa response was determined by a single oral levodopa challenge test with Sinemet® (25/250 mg) in the patients with PD. The motor response evaluated by the time to peak response, the duration and magnitude of the response in the motor part of the Unified Parkinson's Disease Rating Scale; tapping or walking times showed no significant difference between the genotypes. Thus, pharmacokinetic or pharmacodynamic factors other than the investigated genetic variant of the COMT enzyme seem to determine the response to levodopa in PD.

UR - http://www.scopus.com/inward/record.url?scp=0035793491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035793491&partnerID=8YFLogxK

U2 - 10.1016/S0304-3940(00)01749-3

DO - 10.1016/S0304-3940(00)01749-3

M3 - Article

C2 - 11163295

AN - SCOPUS:0035793491

SN - 0304-3940

VL - 298

SP - 131

EP - 134

JO - Neuroscience Letters

JF - Neuroscience Letters

IS - 2

ER -

Genotypes of catechol-O-methyltransferase and response to levodopa treatment in patients with Parkinson's disease

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this